MAY 20, 2013 08:00 AM PDT

Monitoring Heparin in the Clinical Laboratory

C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Associate Professor, College of Medicine Department of Pathology, Immunology and Laboratory Medicine, University of Florida
    Biography
      Dr. Neil S. Harris is board-certified in anatomic and clinical pathology, as well as clinical chemistry through the American Board of Clinical Chemistry. He is currently the director of the core (chemistry/hematology) laboratory, in addition to being a clinical associate professor at the Department of Pathology, Immunology and Laboratory Medicine within the University of Florida's College of Medicine. Dr. Harris received his undergraduate and medical education at the University of Cape Town in South Africa. In the 1980s, his postgraduate training included a residency in clinical pathology (chemical pathology & immunology) in the Division of Pathology at the University of Cape Town. This was followed by a research fellowship in the Division of Hematology/Oncology and a fellowship in clinical chemistry at the Department of Laboratory Medicine at the Children's Hospital in Boston, Massachusetts. He obtained his USA credentials in pathology by completing his residency at Fletcher Allen Health Care in at the University of Vermont in Burlington.

    Abstract:

    Unfractionated heparin (UFH, commonly called heparin) is an indirect anticoagulant commonly administered prophylactically to inpatients at risk of thrombosis.  Anticoagulants, including UFH, are considered high alert medications when used for treatment. As such, assays monitoring levels of UFH are extremely important to avoid adverse effects for patients. This activity will provide improved understanding for clinicians and laboratorians related to the monitoring of UFH and related forms of heparin.  Emphasis will be placed on the role of the chromogenic anti-Xa assay as a measure of heparin activity along with clinical scenarios and outcomes studies.

    • Describe the biochemical nature of heparin including low molecular weight heparin (LMWH) and ultra-low molecular weight synthetic forms such as fondaparinux.
    • Review the anticoagulant mechanism of action of these various forms of heparin.
    • Compare the activated PTT and the anti-Xa assay as a means of monitoring heparin.
    • Explain the role of ATIII supplementation in the anti-Xa assay and its consequences.
    • Discuss the clinical consequences of anti-Xa monitoring in the context of clinical scenarios.

    Show Resources
    You May Also Like
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    MAY 03, 2018 11:00 AM PDT
    MAY 03, 2018 11:00 AM PDT
    DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    AUG 15, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 15, 2018 08:00 AM PDT
    DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
    APR 27, 2018 10:00 AM PDT
    C.E. CREDITS
    APR 27, 2018 10:00 AM PDT
    DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
    APR 25, 2018 07:00 AM PDT
    C.E. CREDITS
    APR 25, 2018 07:00 AM PDT
    DATE: April 25, 2018TIME: 1500 CET, 10:00 a.m. EST, 7:00 a.m. PST Hematology and coagulation laboratories perform a wide range of routine and specialized tests, allowing clinicians to...
    Loading Comments...